通过抑制SIRT1-ubiquitination,CHK1可以减轻心脏功能障碍
Tong-Tong Yang1, Liu-Hua Zhou1, Ling-Feng Gu1
1Department of Cardiology, the First Affiliated Hospital of Nanjing Medical University, Nanjing 210029, China.
Metabolism: clinical and experimental
|October 25, 2024
概括
检查点激酶1 (CHK1) 通过维护线粒体功能来保护心脏免受缺血-再输液 (I/R) 损伤. CHK1通过一种SIRT1依赖的途径实现这一目标,突出了心脏保护的新治疗标.
科学领域:
- 心脏病学 心脏病学
- 分子生物学分子生物学
- 线粒体生物学 线粒体生物学
背景情况:
- 线粒体功能障碍是心肌缺血-反 (I/R) 损伤的关键因素.
- 已知检查点激酶1 (CHK1) 促进心肌细胞增殖,但其在I/R损伤期间对线粒体功能的影响尚不清楚.
研究的目的:
- 研究CHK1在调节线粒体功能和心肌细胞在I/R损伤后的存活率方面的作用.
- 阐明CHK1影响线粒体平衡和心脏保护的分子机制.
主要方法:
- 产生心肌细胞特异性CHK1淘汰和过度表达的小鼠模型.
- 隔离成年小鼠心肌细胞用于体外氧气-葡萄糖剥夺/再氧化 (OGD/R) 研究.
- 利用质谱-蛋白质组学和共免疫沉试验来识别分子标和相互作用.
主要成果:
- 在I/R受损心肌和OGD/R压力心肌细胞中,CHK1表达减少.
- 过度表达CHK1可以防止I/R损伤,而CHK1缺乏会加剧心脏功能障碍和亡.
- CHK1保留了线粒体新陈代谢,减轻了氧化应激,促进了线粒体生物发生和线粒体,确定了SIRT1作为由CHK1酸化的直接标.
结论:
- 通过增强线粒体功能和促进心肌细胞存活,CHK1减轻心肌细胞I/R损伤.
- CHK1的保护作用通过一种依赖SIRT1的机制进行介导,包括抑制SIRT1降解.
- 这些发现确立了CHK1作为线粒体动态的关键调节器和I/R损伤的潜在治疗标.
更多相关视频
05:58Mouse Electroacupuncture Fixation Device Fabrication for Electroacupuncture Pretreatment in Diabetic Cardiomyopathy Mouse Model
Published on: April 18, 2025
119
07:40Protection of H9c2 Myocardial Cells from Oxidative Stress by Crocetin via PINK1/Parkin Pathway-Mediated Mitophagy
Published on: May 26, 2023
1.1K
相关概念视频
01:26Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
394
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
394
01:17Pathophysiology of Heart Failure
1.5K
Heart failure (HF) is a progressive syndrome involving ventricles that leads to inadequate cardiac output. It can be classified based on location and output or ejection fraction. Ejection fraction (EF) is an essential measurement in the diagnosis and surveillance of HF. Reduced EF corresponds to systolic heart failure (HFrEF). However, HF with preserved ejection fraction (HFpEF) is becoming increasingly prevalent. Also known as diastolic HF, this form of HF is related to aging. The...
1.5K